Evidance health sciencesPub Date : 2026-01-01Epub Date: 2026-04-02DOI: 10.65416/ehealthsci.2026.944313
Mona Abdullrahman Alromaihi, Yazan J Alalwani, Manal Mudhhi Almazrui, Layan Bandar Alzahrani, Abdulaziz A Alzahrani, Alwaleed Alotaibi, Shahad Tariq Harun, Dena Nasser Alhadlah, Arwa Ali Alshehri, Naif Abdullah Alrommani, Mohammed Salem Barabea, Ethar Ghazi Alharbi, Ahmed Y Azzam
{"title":"Target Trial Emulation Meta-Analysis of Benzodiazepines For Out-of-Hospital Status Epilepticus in Adults.","authors":"Mona Abdullrahman Alromaihi, Yazan J Alalwani, Manal Mudhhi Almazrui, Layan Bandar Alzahrani, Abdulaziz A Alzahrani, Alwaleed Alotaibi, Shahad Tariq Harun, Dena Nasser Alhadlah, Arwa Ali Alshehri, Naif Abdullah Alrommani, Mohammed Salem Barabea, Ethar Ghazi Alharbi, Ahmed Y Azzam","doi":"10.65416/ehealthsci.2026.944313","DOIUrl":"10.65416/ehealthsci.2026.944313","url":null,"abstract":"<p><strong>Introduction: </strong>Benzodiazepines represent the first-line management for status epilepticus; however, heterogeneity in study designs has resulted in conflicting efficacy estimates. We aimed to conduct a target trial emulation meta-analysis to quantify design-induced bias and estimate the efficacy of benzodiazepines for adults in out-of-hospital settings under an ideal double-blind randomized controlled trial (RCT) setting.</p><p><strong>Methods: </strong>Following PRISMA 2020 guidelines, we searched PubMed, Scopus, Web of Science, Cochrane Library, and Google Scholar up to November 25, 2025. Studies evaluating benzodiazepines for status epilepticus in adults were included. The T3-Meta framework was utilized to model design features as bias covariates, with the target trial effect (θ*) representing seizure cessation rates under ideal RCT conditions. Network meta-analysis was used to evaluate comparative effectiveness.</p><p><strong>Results: </strong>Fourteen studies (2,803 adult patients) were included. Traditional random-effects pooling demonstrated a seizure cessation rate of 68.8% (95% confidence interval [CI]: 63.2-74.0%, I<sup>2</sup>=82.0%). Target trial analysis revealed significant open-label bias (β = 0.757, odds ratio [OR]=2.13, P=0.048), with the bias-adjusted θ* of 64.9% (95% CI: 53.9-74.6%, I<sup>2</sup>=41.5%). Design features explained 49.4% of the between-study heterogeneity. Network meta-analysis demonstrated midazolam superiority over lorazepam (OR=1.60, P=0.001) and diazepam (OR=2.21, P=0.002). Midazolam achieved the highest P-Score (96.2%), followed by lorazepam (50.9%) and diazepam (2.9%).</p><p><strong>Conclusions: </strong>Traditional meta-analysis was found to overestimate benzodiazepine efficacy by 3.9 percentage points due to open-label design bias. Intramuscular midazolam demonstrated superior effectiveness compared to intravenous lorazepam and diazepam for status epilepticus in adults.</p>","PeriodicalId":521365,"journal":{"name":"Evidance health sciences","volume":"1 1","pages":"16-32"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13120326/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147795910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Evidance health sciencesPub Date : 2026-01-01Epub Date: 2026-04-05DOI: 10.65416/ehealthsci.2026.117757
Yazan J Alalwani, Shimah Maibed Alsalhi, Nawaf Salem Baradhwan, Rahaf Muqbil Alsubaie, Norah Abdullah Alhweish, Rawan Abdullah A Jarah, Lujain Abdulrahman Alsarhan, Reem Mohammed A Albarrak, Zahra Shafiq Yousef Almatar, Njood Mohammed Faleh Alhajri, Rahaf Abdullah Ali Alshahrani, Eiman Mohammed AlShammari, Ahmed Y Azzam
{"title":"National Burden of Breast Cancer in Saudi Arabia, 1990-2023, With Forecasts to 2050: A Systematic Analysis for the Global Burden of Disease Study 2023.","authors":"Yazan J Alalwani, Shimah Maibed Alsalhi, Nawaf Salem Baradhwan, Rahaf Muqbil Alsubaie, Norah Abdullah Alhweish, Rawan Abdullah A Jarah, Lujain Abdulrahman Alsarhan, Reem Mohammed A Albarrak, Zahra Shafiq Yousef Almatar, Njood Mohammed Faleh Alhajri, Rahaf Abdullah Ali Alshahrani, Eiman Mohammed AlShammari, Ahmed Y Azzam","doi":"10.65416/ehealthsci.2026.117757","DOIUrl":"10.65416/ehealthsci.2026.117757","url":null,"abstract":"<p><strong>Introduction: </strong>Breast cancer represents the most common malignancy among Saudi Arabian women; however, structured population-level burden assessments integrating advanced epidemiological methods remain limited. We quantified the growing burden of breast cancer in Saudi Arabia from 1990 to 2023 and projected trends to 2050.</p><p><strong>Methods: </strong>Using Global Burden of Disease 2023 estimates, we analyzed incidence, mortality, and disability-adjusted life-years (DALYs) through joinpoint regression, age-period-cohort modeling, and Das Gupta decomposition. Forecasts utilized Bayesian model averaging across four statistical models. Healthcare system performance was assessed via mortality-to-incidence ratio trajectories against socio-demographic index benchmarks.</p><p><strong>Results: </strong>Incident cases increased from 454 (95% Uncertainty Interval [UI]: 322-630) in 1990 to 4,168 (3,009-5,990) in 2023, representing an 818% increase. Age-standardized incidence rose from 6.47 to 19.58 per 100,000 (+203%). Deaths increased from 243 to 1,197 (+393%), while DALYs rose from 8,524 to 43,561 (+410%). The mortality-to-incidence ratio improved from 0.535 to 0.362 (-32%), indicating enhanced survival. Age effects explained 77.7% of variance in incidence patterns, with period effects contributing 20.6%. Decomposition attributed 44% of the incidence increase to population growth, 48% to epidemiological change, and 7% to aging. Performance frontier analysis identified 659 preventable deaths annually (57% of total) if Saudi Arabia achieved benchmark efficiency. Ensemble forecasts project stabilization at 19.3 per 100,000 by 2050.</p><p><strong>Conclusions: </strong>The breast cancer burden in Saudi Arabia has increased significantly, driven primarily by true epidemiological change and population growth. Despite improving survival, significant preventable mortality persists, necessitating enhanced screening and treatment optimization.</p>","PeriodicalId":521365,"journal":{"name":"Evidance health sciences","volume":"1 1","pages":"33-54"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13148422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147849378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}